Getting it right: Recommendations for a European BARDA

Our fifth dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

Will the EU be a wise investor in biomedical R&D or a passive donor? How can we guarantee a public return on public investment? 

As the EU considers establishing an Agency comparable to the U.S. Biomedical Advanced Research and Development Authority (BARDA), we will outline a set of recommendations on how to get it right.